-

Be Biopharma to Present at the 20th Annual WORLDSymposium™ 2024

SAN DIEGO--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a company pioneering the development of engineered B Cell Medicines (BCMs), today announced that it will present at the 20th Annual WORLDSymposium™ being held February 4-9, 2024, in San Diego, California.

Details regarding the Be Biopharma presentation at the conference are as follows:

Title: Development of an ex vivo precision gene engineered B cell medicine that produces highly active and sustained levels of acid sphingomyelinase for the treatment of Neimann-Pick disease
Presenter: Monika Musial-Siwek, Ph.D., Director, Protein Sciences, Be Biopharma
Date: Thursday, February 8, 2024
Time: 1:00 – 2:00 PM PT

For more information, please visit the conference website worldsymposia.org.

About Engineered B Cell Medicines – A New Class of Cellular Medicines

The B cell is a powerful cell that produces thousands of proteins per cell per second at constant levels, over decades. Precision genome editing can now be used to engineer B Cells that produce therapeutic proteins of interest, driving a new class of cellular medicines – Engineered B Cell Medicines (BCMs) – with the potential to be durable, allogeneic, redosable and administered without pre-conditioning. The promise of BCMs could transform therapeutic biologics with broad application — across protein classes, patient populations and therapeutic areas.

About Be Biopharma

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BCMs) to dramatically improve the lives of patients who are living with Hemophilia B and other genetic diseases, cancer, and other serious conditions. With eyes locked on the patient, our team of purpose-driven scientists, technologists, manufacturing experts and business builders collaborate to create a bold new class of cell therapies. Be Bio was founded in October 2020 by B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., from Seattle Children’s Research Institute. Be Bio is backed by ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, Takeda Ventures, Seattle Children’s Research Institute and others. Since our founding, Be Bio’s investors have committed over $180 million to enable the Company to re-imagine medicine based on the power of B cell therapy. For more information, please visit us at Be.Bio and our LinkedIn page.

Contacts

Investor Contact:
ir@be.bio

Media Contact:
media@be.bio

Industry:

Be Biopharma, Inc.

Release Versions
English

Contacts

Investor Contact:
ir@be.bio

Media Contact:
media@be.bio

More News From Be Biopharma, Inc.

Be Bio Announces First Participant Dosed in BeCoMe-9 Trial of BE-101 in Hemophilia B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio” or “the Company”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the first participant was treated with BE-101 in the BeCoMe-9 Phase 1/2 clinical trial. BE-101 was administered without any preconditioning or immunosuppression, supported by preclinical evidence that BCMs engraft in the absence of these burdensome regimens. BeCoMe-9 is a multi-center, first-in...

Be Biopharma Announces New Preclinical Data for BE-102, a B Cell Medicine for the Potential Treatment of Hypophosphatasia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today presented results from new preclinical research demonstrating a single administration of BE-102, a BCM for the potential treatment for Hypophosphatasia (HPP), produces continuous levels of active ALP long-term in vivo. The findings will be presented during an oral presentation at the American Society of Gene & Cell T...

Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting being held in New Orleans, May 13-17, 2025. Details regarding the Be Biopharma presentations at the conference are as follows: Oral Presentation Title: Ex Vivo Gene Editing of Autologous B Cells Produce Sustained L...
Back to Newsroom